FDA Approves Drug for Facilitating Intubation

Article

The prescription drug is indicated for facilitating tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Officials with the FDA have approved Nivagen Pharmaceuticals’ succinylcholine chloride injection USP 200 mg/10 mL. The prescription drug is indicated for facilitating tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Adverse effects of succinylcholine chloride injection include anaphylaxis, hyperkalemia, and malignant hyperthermia.

According to the FDA, the agency recognizes the increased demand for certain products during the coronavirus disease 2019 (COVID-19) pandemic, and it remains deeply committed to facilitating access to medical products to help address critical needs of the American public.

REFERENCE

Coronavirus (COVID-19) Update: Daily Roundup May 19, 2020 [news release]. Silver Spring, MD; May 19, 2020: FDA website. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-19-2020 Accessed May 20, 2020.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.